At high-stakes table, growing Peninsula biotech antes up with 'fatty-liver' drug
Even before morbidly overweight people lose pounds through gastric bypass surgery — within only a couple days of the procedure — they shed obesity-related diabetes.
Tagging the phenomenon to a specific hormone led to the founding 10 years ago of NGM Biopharmaceuticals Inc. The company developed its own version of the hormone, engineering out the hormone's connection to a hig her risk of liver cancer.
Click here to get the free daily TechFlash Silicon Valley newsletter.
But instead of pushing…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Diabetes | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Gastric (Stomach) Cancer | Gastric Bypass | Gastroenterology | Health Management | Hormones | Liver | Obesity | Pharmaceuticals | Urology & Nephrology